In order to have the flexibility to opportunistically allocate excess capital to share repurchases, the company announced that its board of directors has authorized a new share repurchase plan under which the company may repurchase up to $125M of the company’s outstanding common stock.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks announces strategic initiative to optimize Ziihera cash flows
- Zymeworks appoints Scott Platshon as acting chief investment officer
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
- Zymeworks Stock Upgraded to ‘Buy’ on Promising Phase 3 Trial Results and Financial Prospects
- Zymeworks price target raised to $42 from $30 at Jefferies